IPCA Laboratories Ltd launches Diulcus to address Diabetic Foot Ulcer (DFU) in India
Mumbai, August 17, 2024: As per the ICMR-INDIAB (2023) study, 10 crore people in India suffer from diabetes, with an additional 13.6 crore people affected by pre-diabetes. This significant health concern positions India to become the diabetes capital of the world by 2030. In response to this serious healthcare challenge, IPCA Laboratories Ltd proudly announces the launch of Diulcus, a novel product aimed at addressing the challenges of Diabetic Foot Ulcer (DFU) in the Indian market. Diulcus, developed by NovaLead Pharma Pvt Ltd, a pioneer in drug repurposing, represents a significant advancement in the management of DFU. The product has received approval from the Central Drugs Standard Control Organization (CDSCO) and was partially funded by the Biotechnology Industry Research Assistance C...










